Skip to content

ENVERIC BIOSCIENCES, INC.: 10-Q filed 2021-11-15

What ENVERIC BIOSCIENCES, INC. reported in its quarterly report filed 2021-11-15 (fiscal Q3 2021): 29 published measures, 79 facts as tagged in accession 0001493152-21-028263.

This filing

Form
10-Q (quarterly report)
Filed
2021-11-15
Fiscal period
fiscal Q3 2021
Accession
0001493152-21-028263 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ENVERIC BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-09-3069,757,704USD
At 2020-12-314,096,891USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-09-3014,390,855USD
At 2020-12-31681,250USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-09-3055,366,849USD
At 2021-06-3018,818,988USD
At 2021-03-3118,991,678USD
At 2020-12-313,415,641USD
At 2020-09-30-3,589,158USD
At 2020-06-30-3,482,013USD
At 2020-03-31-2,699,278USD
At 2019-12-31-1,811,601USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-2,712,406USD92
2021-01-01 to 2021-09-30-6,871,406USD273
2021-04-01 to 2021-06-30-908,289USD91
2021-01-01 to 2021-03-31-3,250,711USD90
2020-07-01 to 2020-09-30-565,335USD92
2020-01-01 to 2020-09-30-2,482,187USD274
2020-04-01 to 2020-06-30-818,391USD91
2020-01-01 to 2020-03-31-1,098,461USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-09-30-7,390,358USD273
2020-01-01 to 2020-09-30-1,638,798USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-09-3024,899,652USD273
2020-01-01 to 2020-09-301,932,196USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-09-302,380,327USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-09-30-18,630,963USD
At 2020-12-31-11,759,557USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-09-30140,568USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-01-01 to 2021-09-304,829,484USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-3,516,869USD92
2021-01-01 to 2021-09-30-13,644,877USD273
2020-07-01 to 2020-09-30-489,834USD92
2020-01-01 to 2020-09-30-2,094,044USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-09-3022,281,542USD
At 2020-12-312,279,170USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2021-07-01 to 2021-09-30370USD92
2021-01-01 to 2021-09-305,191USD273
2020-07-01 to 2020-09-3075,501USD92
2020-01-01 to 2020-09-30388,143USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-09-302,162,812USD
At 2020-12-31681,250USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2021-09-309,061,927USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2021-09-3038,273,667USD
At 2020-12-311,817,721USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2021-07-01 to 2021-09-302,123,834USD92
2021-01-01 to 2021-09-3010,864,696USD273
2020-07-01 to 2020-09-30426,532USD92
2020-01-01 to 2020-09-301,959,785USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-07-01 to 2021-09-301,219,339USD92
2021-01-01 to 2021-09-302,295,826USD273
2020-07-01 to 2020-09-3063,302USD92
2020-01-01 to 2020-09-30134,259USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-09-3031,383,632shares
At 2020-12-3110,095,109shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-09-3073,869,289USD
At 2020-12-3115,222,770USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2021-09-30-185,313USD
At 2020-12-31-181,277USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-09-302,240USD
At 2020-12-310USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2021-09-3038,273,667USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2021-09-30833,116USD
At 2020-12-31700,710USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2021-07-01 to 2021-09-30-2,718,916USD92
2021-01-01 to 2021-09-30-6,875,442USD273
2020-07-01 to 2020-09-30-572,645USD92
2020-01-01 to 2020-09-30-2,512,264USD274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2021-07-01 to 2021-09-30170,692USD92
2021-01-01 to 2021-09-30481,351USD273
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2021-07-01 to 2021-09-30804,463USD92
2021-01-01 to 2021-09-306,773,471USD273
2020-07-01 to 2020-09-30-75,501USD92
2020-01-01 to 2020-09-30-388,143USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2021-01-01 to 2021-09-305,191USD273
2020-01-01 to 2020-09-30388,143USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2021-01-01 to 2021-09-3021,614,488USD273
2020-01-01 to 2020-09-30227,500USD274

Inspect the source

Entity
ENVERIC BIOSCIENCES, INC. / CIK 0000890821
Captured
2026-09-20T05:03:46.618Z
SEC response SHA-256
ed23dbf99f9ce404ef7949b5b1b4b3a643f25caca94a6c8cd8444309157de101

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000890821.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))